These correlations were also observed in another study (6), which highlighted that in patients with myasthenic syndromes the use of anti–PD-1/PD-L1 was more prevalent, in the cohort of patients with meningitis the use of anti–CTLA-4 predominated, while in patients who developed cranial neuropathies exposure to anti-PD-1/PD-L1 and anti-CTLA-4 was more frequent compared to the entire examined sample. The gene discussed is CTLA4; the disease is cranial nerve neuropathy.